eCRF Completion Guidelines

Client: Connect Biopharma

Protocol: CBP-201-206

Clinical Data Management System (CDMS):
Medrio

Prepared by:

Celissa Williams
Principal Clinical Data Manager
Precision for Medicine (Precision)
Phone: +1 (919) 931-8641
Email: Celissa.Williams@precisionformedicine.com

Version: 1.0_02JUN2025

CCG APPROVAL
The signatures below indicate approval of the CCG file titled: Connect Biopharma eCRF Completion Guidelines_V1.0_02JUN2025.pdf

Signed by:
Celissa Williams
Signer Name: Celissa Williams
Signing Reason: I am the author of this document
Signing Time: 02-Jun-2025 | 4:14:56 PM PDT
474BE319B697474A96CD69EFE54052A7

	02-Jun-2025
Signature	Date
Celissa Williams	Principal Clinical Data Manager

Precision for Medicine

Signed by:
Bryn Natale
Signer Name: Bryn Natale
Signing Reason: I approve this document
Signing Time: 02-Jun-2025 | 2:32:04 PM PDT
B9E47875BC2441C38B78B2B0F66E5618

	02-Jun-2025
Signature	Date
Bryn Natale	Clinical Trials Asst Manager

Connect Biopharma

REVISION HISTORY

Version	Summary/Reason for changes	Revision Date
V1.0	Initial Approval	NA

TABLE OF CONTENTS

Overview

The purpose of the eCRF Completion Guidelines (CCGs) is to provide instructions on how to complete the eCRFs for the CBP-201-206 Connect Biopharma project, whereby Precision for Medicine (Precision) is contracted for data management services. It also provides some general overview information and instructions on how to use the Electronic Data Capture (EDC) used for collecting the participant data for this clinical trial. The EDC training set up for this project should be referenced for further instructions on how to use the database based on the user's assigned role.

DM Team Personnel

The primary data management team member(s) for this project are:

Name	Position	Responsibility
Celissa Williams Precision Phone: +1 (919) 931- 8641 Email:celissa.williams@precisionformedicine.com	Lead Data Manager (LDM)	Data management activities from database open, conduct, through database lock.
Syed Aamir Precision Phone: +1 (289) 943-1699 Email:syedaamir.qadri@precisionformedicine.com	Data Management Oversight (DMO)	Oversee data management activities from database open, conduct, through database lock. May serve as the back-up.

Medrio

Medrio is the web-based EDC database selected by the Sponsor to collect clinical data for this project. Designated project team members responsible for collecting, cleaning, and/or reviewing the data and project progress will have role-based access to the EDC (e.g., CRA, DM, Study Coordinator, PI, etc.).

Getting Started

Supported Browsers

This EDC supports all commonly used browsers e.g., Microsoft Edge (formerly Internet Explorer), Firefox (Mozilla), Chrome (Google), Safari (Apple). It is highly recommended that

the latest versions available are used and the browser software is up to date with any vendor updates, especially those concerning security.

Browser	Version
Microsoft Edge	9 and later
Firefox (Mozilla)	27 and later
Chrome (Google)	30 and later
Safari	7 and later

Accessing Your Project

Study Database

Participant data for this study will be entered into the Medrio EDC application. This application is accessed using a web-based portal called Medrio. You will have access to this portal over the internet using a standard internet browser such as Google Chrome or Firefox. No software needs to be installed locally. The Medrio portal can be found at the following location: https://identity.medrio.com/identity/login?signin.

Below is an example of Medrio login page.



Tip: save the Medrio Internet address as a browser ‘Favorite’ or ‘Bookmark’ to keep it easily accessible throughout the study.

Permissions and project access to the EDC are granted by the Lead Data Manager (LDM) after EDC training is completed by the intended user and a signed training form has been returned to the LDM.

When access is granted to a project, the user will receive an automated email from "Database System Administrator (Medrio system)" with instructions on how to set up your account and profile. If the LDM has set up permissions and you did not receive the email, check your junk and/or spam email folders in the event it routed there inadvertently. If you still have not received it, contact your CRA who will reach out to the project LDM for access request. The following is an example of the email you will receive:



[EXTERNAL EMAIL] DO NOT CLICK links or attachments unless you recognize the sender and know the content is safe.

Welcome to Medrio!

Just so you know, your Medrio account's been granted access to a new study set up by precisionformedicine.com.

All you have to do to login is:

- click the link below or copy and paste the address into your browser
- log in using the username below and your existing password

URL: https://Connect-Asthma-CBP-201-206-Connect-TEST.custom.medrio.com

USERNAME:

STUDY: TEST- Connect-Asthma-CBP-201-206

If you have questions about logging in, please contact your study coordinator for further assistance.

Thanks,

The Medrio Team

To access the EDC database, click on the link provided in the email and/or open a web browser and copy paste the link:

https://Connect-Asthma-CBP-201-206-Connect Biopharma-LIVE.custom.medrio.com

Enter the username provided in the Welcome to Medrio email.

First Time Login

Access to Medrio is by invitation only set up by Precision DM. As a new user, you cannot log in until you receive an email and click the link to accept the invitation to join Medrio. If you need access to the study, please contact your CRA to request user activation/invitation from Precision DM. Once Precision DM completes the user activation process, an e-mail invitation will be sent from the following e-mail address: Medrio system, no-reply@mail.medrio.com. You are then redirected to an activation web page where you create your username and password and register

as a Medrio user. If the Precision DM has set up permissions and you did not receive the email, check your junk and/or spam email folders in the event it routed there inadvertently. If you still have not received it, contact the study CRA who will follow-up the issue with the LDM to re-send the invitation email.

Activating your Medrio Account:
1. Open your invitation email.
2. Click the link or copy and paste the address into your browser.
3. Set up your account and choose a password.
   - Passwords must: be at least ten (10) characters in length,
   - contain at least three of the following four items: uppercase letter, one lowercase letter, one character and one number,

Complete all required fields on the activation page. E-learning required training needs to be completed (if not completed earlier) before access to the study EDC database can be granted.

Accessing eLearning in Medrio:

- Go to ‘Help’ tab on top left corner of Medrio
- Click on ‘Medrio Community’ from the drop-down option



- Click on ‘Training’ and select ‘Learning Center’ from the
- Select role specific training from Medrio eLearning Home page.



After eLearning is complete, site staff should generate their training certificate (in pdf format) for Medrio training and send it to their CRA for filing in the Trial Master File.

Subsequent Logins

Once you register as a Medrio user, log in by entering your username and password on https://medrio.com. You must accept the End User License Agreement (EULA) the first time you log in. All subsequent invitations and assignments appear on your Medrio home page.

Changing Your Password

To change your password, click on the user's name at the top right corner of the screen. Click 'Change Your Password.' A pop-up window will appear.



Password Reset

Users can reset their own passwords by providing answers to security questions they set up upon account creation.

The user password automatically expires after 90 days. Users are notified of the expiration when they log into Medrio and are taken to a page to create a new password. The last two passwords may not be reused when resetting passwords.

EDC Support / Help

For protocol related questions, please contact your site CRA. For Medrio related questions, please contact the Lead Data Manager, Celissa Williams: Celissa.Williams@precisionformedicine.com

If your study administrator is unable to assist you, please submit a ticket to Medrio Support.

|Medrio Support | email: support@medrio.com | website: http://medrio.com/contact/contact.html | phone: Toll Free: 877-763-3746

Site-Level Access

Users are granted access to specific sites and participants based on their role and permissions in the project. If a user has access to only specific sites, then they can only access the forms (eCRFs) and data for the participants who are assigned to those specific sites. If they have permissions to run reports, the report output will only show the results of the participants and sites they have access to view as well.

Getting More Help

The 'Help' tab at the top right upper corner of the page is available to assist with any questions.

Alternatively, you may contact:

- Your Project Assigned CRA
- Lead Data Manager and Back up DM as noted in the DM Team Personnel section

These links are available on all pages within the database:

- Help for this page – provides help for the page you are currently on
- Documentation – opens a new page, providing access to the Medrio EDC Main User guide
- Medrio Community – opens a new page, providing access to Medrio discussion boards
- Icon Legend – explanation of system and display icons
- System Maintenance – opens a screen providing timing for upcoming scheduled maintenance
- System Requirements – software requirements to use Medrio
- Release Notes – opens a new page, provides information on Medrio release documentation
- Privacy Policy – opens a new page, provides access to the Medrio privacy policy statement
- Contact Us – provides contact information for support



The full list of system icons can be accessed by clicking Icon Legend in the screen shot above.

Home page

The Home page is the first page a user will see upon login. What appears on the Home page depends upon user permissions and roles. The Home page of a Clinical Research Associate (CRA) is displayed in the example below:



Creating a New Participant

Participant/Subject IDs will be automatically generated using the Interactive Response Technology (IRT).

Participant data will not be available for entry in EDC until they are enrolled through the IRT.

Accessing Participants

The 'Home' tab is a portal screen that gives information on Enrolled Subjects, Data Entry, and Queries. You can also access participant data from this screen by selecting the Participant/Subject ID.

Once the ID is selected, you can then begin to 'Enter Data.'



Enter Data Tab

The 'Enter Data' tab provides a Subject Listing (where you can click on a participant to go into the records for that participant) and 'Tabular' (where you can adjust data entry views). To begin data entry for a CRF, select that form.



To view all participants' data at your site use option 'Site Matrix':



Matrix View Icons

Icon	Name	Description
●	Complete Final	In Forms Complete mode: All forms at the visit are in a complete status - either "Complete", "Complete – Final" or combination of "Complete", "Complete-Final" and "Not Expected". In Data Entered mode: All forms at the visit have data entered.
◉	Not Expected	All forms for the visit are marked "Not Expected".
◒	Partially Complete	In Forms Complete mode: Some forms at the visit have data entered, but not all forms are yet marked complete. In Data Entered mode: Some forms at the visit have data entered.
○	Not Entered	In Forms Complete mode: No forms have been marked complete or not expected. In Data Entered mode: No forms at the visit have data entered.

To view data entry status for a particular participant, select option ‘Tabular’:



To view a participant’s data use option ‘Matrix’:



Manage Tab

The 'Manage' tab provides Study Management Options and Reports.

The Study Coordinator view is below:



General eCRF Entry Guidelines

All requested fields on the eCRF should be completed. It is best practice to enter data in the order of the eCRF page from top to bottom. This can help avoid missing fields inadvertently. The eCRFs are designed with *skip logic*, meaning that as data is entered on the eCRF in order, subsequent data may grey out to be omitted from data entry. All requested data fields on the eCRF must be completed. Fields with a red asterisk * are required and must be entered before saving the eCRF.

All information must be entered in English. Attention to correct spelling and accurate information is important. Where appropriate, use clear and concise medical terminology. Do not use abbreviations. The TAB key may be used to advance to the next field. Answer every question as applicable. Do not leave spaces or blank boxes unless specified.

It is important to try to enter all data required on the page and address all queries as they arise. A page will only be saved with a [Complete] status when there are no missing data fields or there are no open queries on the eCRF. A page will reflect the status of Not Complete when the eCRF is partially completed or queries are pending.

Source Documentation

According to the Food and Drug Administration (FDA) regulations, all data entered on eCRFs must be verifiable in study participants' medical records; therefore, detailed source documentation is required. Source documentation may consist of progress notes, data collection worksheets, laboratory printouts, or additional records from which data are extracted at the study site and entered the eCRF. Each participant's medical record must clearly indicate the date the participant gave his/her consent to participate in the study, including the study number. A dated entry must be made in the participant's medical record for each study visit, and accompanying source documentation must be maintained. Source documentation must be available to the CRA for inspection during monitoring visits to verify eCRF entries.

Leading Zeroes

If a leading zero is entered for a numeric field, once the page is saved the leading zero will be dropped. For instance, a Systolic Blood Pressure entry of [090] will be saved as [90]. Note for sites in Europe - numbers use a decimal point (.), not a comma (,) to separate the whole number from the fractional number, e.g., 27.6 kg. Use leading zero before decimal if number is lower than 1, e.g., 0.37.

Radio Buttons

eCRF fields are set up as Radio Buttons, these are designed typically for selecting from a list of choices. It can either be one choice or all that apply. If you would like to remove a selected choice, hold down the *Ctrl* key on your keyboard while clicking the selected value. This will delete the previous choice entered.

Keyboard Shortcuts

There are two keyboard shortcuts for data entry; Ctrl+S for Save, and Ctrl+N for Save & Next. Buttons with keyboard shortcuts are indicated with an underscore beneath the shortcut letter (see Ctrl+S example below).

Dates

Complete dates are required on study expect where specified. The date format is DD/MMM/YYYY (e.g. 01/JAN/2025).

Certain date fields for this project have been configured to accept partial dates. These dates are noted within the CCG instructions for those particular eCRFs.

If part of a date is unknown, the Month and/or Day can be entered as [UN] or [UNK]. A minimum entry of Year is required.

Any date field that is not set up to accept partial dates will fire a query when partial dates are entered. If the year is unknown and nothing is entered, a query will auto-fire. Respond to the query stating no information is known about the desired date.

To enter the date, you may either:

- Utilize the calendar icon next to each date field to select the date you wish to enter, and it will pre-fill the date
- Some date fields have a [Today] shortcut button. If selected, it will enter the current date at time of data entry.

Type the date in the form using DD/MMM/YYYY format.



Time Format

Times must be entered in a 24-hour clock format (00:00-23:59), see table below for conversions. If the time is unknown and nothing is entered, a query will auto-fire. Please respond to the query stating no information is known about the desired time.

AM TIME	24-Hour Time		PM TIME	24-Hour Time
12:00 AM	00:00		12:00 PM	12:00
1:00 AM	01:00		1:00 PM	13:00

2:00 AM	02:00		2:00 PM	14:00
3:00 AM	03:00		3:00 PM	15:00
4:00 AM	04:00		4:00 PM	16:00
5:00 AM	05:00		5:00 PM	17:00
6:00 AM	06:00		6:00 PM	18:00
7:00 AM	07:00		7:00 PM	19:00
8:00 AM	08:00		8:00 PM	20:00
9:00 AM	09:00		9:00 PM	21:00
10:00 AM	10:00		10:00 PM	22:00
11:00 AM	11:00		11:00 PM	23:00

Log and Repeat eCRFs

Logs are repeat style eCRFs that are typically not tied to a particular visit but can be added and updated as much as needed throughout the course of the project. Adverse Events, Concomitant Procedures and Concomitant Medication are common types of log (repeat) pages. Although these eCRFs are not tied to a particular visit, ensure these pages are up to date throughout the course of the project. If more log eCRFs are needed, you are to create as many repeat forms "pages" as needed for Adverse Events. See the section on Adverse Events for more information.

Inactivate/Reactivate Loglines

To **delete a record** on a log form if a line was added by mistake:

1. Click the trash can icon on the left of each log line
2. A warning box will appear asking you to confirm the deletion.
3. The record will be removed including the assigned log line identifier.







NOTE: Once a log line has been deleted, it cannot be retrieved. If deleted in error, you will need to re-enter the data in the eCRF.

Unscheduled eCRFs

The Unscheduled eCRFs should be used for data collected outside of the regular scheduled study visits per protocol. Select as many eCRFs as needed to capture the assessments performed at the Unscheduled Visit. The following eCRFs are available under the Unscheduled eCRFs Section:

- Unscheduled Visit
    - Enter this CRF first to trigger the applicable data collected within the Unscheduled visit from the below options:
        - 12-Lead ECG (Local Lab)
        - Biomarker Sample
        - Chemistry (Local Lab)
        - Chest X-ray or CT

- Health Care Resource Utilization
- Height and Weight
- Hematology (Local Lab)
- Immunogenicity Sample (ADA and NAb)
- Index Asthma Exacerbation Follow-Up
- Injection Site Reaction (ISR)
- Laboratory Tests
- Physical Exam
- PK Sample
- Pregnancy Test
- PRO - ACQ-5
- PRO - Modified Borg Dyspnea Scale
- Smoking Status Changes
- Spirometry/FeNO
- Subsequent Asthma Exacerbation Episode
- Urinalysis (Local Lab)
- Vital Signs

Other, Specify Fields / Yes/No Questions

Per EDC design, if you enter in an "Other, Specify" comment, but then select a corresponding response field is not "Other," the data entered in the "Other, Specify" comment field will be removed. Ensure you select the proper choice option before you enter comment text, this will prevent an entry error and inadvertently lose text entered in the other specify comment text field.

The same EDC design also applies to Yes/No and related questions. If you entered the date before you enter the initial yes/no question, then select No, the supporting data you entered will be removed. As noted in the general eCRF entry guidelines, it is best to enter data in order of the eCRF from top to bottom.

CRF Book / Visit Map

This EDC is integrated with the Suvoda IRT.
In order to enter a participant in EDC, the participant must first be registered through the IRT system.

Once a participant is created in IRT, the record will be automatically created in the Medrio EDC. Upon record creation, you will have access to enter data in the Subject Information and Log Forms folders. The IRT will automatically populate the following fields:

- Participant/Subject ID
- Randomization Date
- Randomization Number

- Age At Screening
- Sex
- What is the participant's Smoking History?
- Kit Number 1:
- Kit Number 2:
- Replacement Kit Number 1A (if applicable)
- Replacement Kit Number 2A (if applicable)
- Replacement Kit Number 1B (if applicable)
- Replacement Kit Number 2B (if applicable)
- Re-screen Participant ID #1 (if applicable)
- Re-screen Participant ID #2 (if applicable



Enter all required fields on the [Informed Consent] eCRF to trigger the appropriate Screening Channel in the participant's schedule. If V1a is selected for [Screening Channel], the V1a visit folder will populate. If V1b is selected [Screening Channel], the V1a visit will be skipped in the participant's schedule and the V1b visit will appear next.

Enter all Subject Information eCRFs prior to populating data in the Screening V1a or V1b visit. Once a Screening channel is selected, Unscheduled Visits will be available for data entry.

Within each participant schedule folder, first populate the [Visit Date] eCRF.

- Once confirmed that the visit occurred, add the [Visit Date:] and the remaining eCRFs for the visit will appear in the participant's schedule.
- Once confirmed that the participant will proceed to the next visit, the subsequent visit eCRFs will appear in the participant's schedule.





To trigger the V2 visit, both the [Visit Date] and [Eligibility] eCRF must be submitted at the Screening V1b visit. This will also trigger the V9 and End of Trial visits, as participants may withdraw consent from study visits at any time after V2.



To trigger V3 or V5, certain fields in the Index Asthma Exacerbation form must be completed. Within the V2 visit, enter [Visit Date] with same requirements as above. To trigger subsequent participant schedule visits, also populate the [Index Asthma Exacerbation] eCRF. If [Did the exacerbation result in a hospitalization at V2?] is Yes or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is Yes, then visits V3 and V4 will appear in the participant's schedule. If [Did the exacerbation result in a hospitalization at V2?] is No or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is No, then V3-V4 will be skipped and the V5 visit will appear in the participant's schedule.



To enter Adverse Events, populate the [Any Adverse Events?] eCRF in the Log Forms folder. If yes is selected, the [Adverse Events] eCRF will appear in the folder for entry.
If an Adverse Event is indicated as 'Serious,' the [Serious Adverse Event] eCRF will populate in this folder for entry.



In the event a participant has an Unscheduled Visit, navigate to the bottom of the schedule to the [Unscheduled Visit 1] folder. First, populate the [Unscheduled Visit] eCRF to indicate the [Visit Date:] and select all assessments that occurred. These assessments will then populate within the [Unscheduled Visit] folder. In the event an additional Unscheduled Visit is conducted, answer 'Yes' to the [Did participant have an additional Unscheduled visit?] field on the [Unscheduled Visit] eCRF. This will trigger the next Unscheduled visit folder. This study was built to accommodate 10 Unscheduled Visits. In the event additional Unscheduled Visits are needed, contact your study DM.



Queries

Edit checks are programmed within the database to fire queries if the data entered does not satisfy the edit check customized for this project. They are triggered once the eCRF is saved and/or at the time data is entered in a field. The query icon is a red exclamation point that is located next to the data field that needs to be addressed. This is an example of a query on the [Pregnancy Test Collection Date].



To review and address a query, open the query that has fired by selecting the Query Icon.

Resolving Queries

There are three ways to resolve queries:

1) Changing the data
   - If data entered is not correct and data should be changed per source, click on the data field, update the data, then select the reason why data is changed. Note: Do not enter data to be updated in the query comments. All data should be updated on the eCRF field.

2) Respond to query (No data change)
   - If data is entered correctly as is, per source, respond to the query by entering a comment to confirm data is correct and/or add additional clarification.
   - Click the [Queries Icon], a field information page will pop up. Select the [Respond] button in the upper right corner, enter a Comment, then select Save. Note: Do not enter data in the query comments. All data should be updated on the eCRF.
3) Edit Form
   - If a field and/or form has already been SDV'd and there are queries to resolve post SDV, select [Edit Form] to enable the query to be addressed, select edit options and reason for change, then resolve query – either edit data or respond to query. See screenshots for examples:

Accessing CCGs

In the 'Manage' tab, under Study Management Options, under Study Documents, you will find the study specific CRF Completion Guidelines eCCGs.

Project Specific Information

Screen Failures/Enrolled Participants

Screen failures are defined as participants who signed the ICF to participate in the clinical trial but are not subsequently randomized. These participants are not required to complete the EOT visit assessments. Screen failures should be recorded in the Interactive Response Technology (IRT) according to instructions in the IRT manual.

Participants who initially screen fail for the trial solely due to the ineligible eosinophil count (i1. Eosinophil count of <300 cells/µL) at Screening Visit 1b, are allowed to re-screen no more than twice if they experience another asthma exacerbation, provided it is deemed appropriate by the Principal Investigator.

If re-screened, the participant should be assigned a new participant number in the IRT.

All participants meeting enrollment criteria will be randomized at baseline (V2) to receive treatment with either rademikibart 600 mg SC or volume-matched placebo.

As participants qualify for randomization, they will be assigned to treatment by the IRT System.

Minimum eCRFs required for Screen Failures include:

- Informed Consent
- Demographics
- Eligibility
- Serious Adverse Events, if applicable
- Adverse Events, if applicable

Guidelines -Per Project Specific eCRFs

Visit Date

Visit date is the date a visit occurred. If [Was the Visit performed?] is Yes, complete [Visit Date] and [Will participant continue to the next visit?]. If assessments for a scheduled visit occur over multiple dates, the date of the first assessment should be recorded.

If the visit was not performed, enter the reason. No further CRFs will populate for that visit.
If the participant continues to the next visit, indicating yes for this question will trigger the next visit in the participant schedule to be populated.

Informed Consent

[Participant Number] is an IRT integrated field and is read only.

For [Date Informed Consent Signed], enter the date the participant signed and consented to participate in the study. This date should be before all on-study procedures and dates.

For [For adolescent, Date Informed Assent Signed], enter the date the adolescent participant signed and assented to participate in the study. This date should be before all on-study procedures and dates.
Note: Only one (1) Date should be provided in EDC based on participant's age.

[Informed Consent Version] should correspond to the current informed consent version the participant was consented to. Incremental versions should be rounded down to the whole number (i.e., Version 1.1 consented, select Version 1 in EDC).

Select the correct [Screening Channel] to populate the V1a or V1b screening. Screening Channel V1a is for participants who are consented while in a stable state. Screening Channel V1b is for participants who are consented after having experienced a qualifying exacerbation. This field will trigger the V1a or V1b visit in the participant schedule.

For [Was the participant re-consented?], enter Yes if a new consent has been obtained. Populate the date and informed re-consent version.

The [Participant Re-Screen #1 and #2] are auto generated by IRT in case a participant is re-screened.
These fields will be blank if the participant has not been rescreened.
Note: If the participant has been rescreened twice, Participant Re-Screen #1 will be the most recent prior participant number. If the participant has been rescreened once, Participant Re-Screen #1 will be their prior participant number.

Eligibility

[Protocol Version] should correspond to the protocol version that was effective at the time the participant was consented. Incremental versions should be rounded down to the whole number (i.e., Version 1.1 consented, select Version 1 in EDC).

[Screening Timepoint] is required. Ensure this field matches the current visit where Eligibility is confirmed. Participants who enter the study via Channel V1a will have their eligibility confirmed at V1a, V1b, and again at V2.

If response to [Did participant meet all eligibility criteria?] is Yes at the Screening V1b visit, the V2 visit in the participant schedule will appear for Randomization/Treatment information to be collected.

If response to [Did participant meet all eligibility criteria?] is No, then enter in the data for the Criterion not met.

For criterion number, enter the number listed in protocol sections 7.1 Inclusion Criteria and 7.2 Exclusion Criteria.

The eCRF has pre-defined rows available to enter data for Criterion Not Met. If more rows are needed, select [More Rows] as applicable. If you select 1, then one row will be added to the eCRF, if you select 5 or 10, then that many respective additional rows will be added.



The [Supplemental Screen Failure Reason] field is intended for participants who screen fail for reasons other than, or in addition to, inclusion and exclusion criteria. Reasons such as lost to follow-up, withdrawal of consent, and physician decision can be found here.

Randomization

Eligible participants will be randomized to one of the 2 treatment arms using IRT. [Date of Randomization:] and [Randomization Number:] are IRT integrated fields and are read only.

Participants will be randomized at baseline (V2) to received treatment with either rademikibart 600 mg SC or volume-matched placebo.

Demographics

Enter all requested data fields.

[Date of Birth:] the participant must be greater than or equal to 12 years of age to participate in the study and no older than 75 years inclusive at the time of signing the informed consent/assent form. Enter the participant's birth Month (MMM) and year (YYYY). UNK-YYYY may be entered if birth month is unknown or per local regulation.

[Age At Screening]: This is an IRT integration field and is Read-Only. Data will flow from IRT to EDC.

[Sex:] This is an IRT integration field and is Read-Only. Data will flow from IRT to EDC.
If Female, please indicate if the participant is of childbearing potential.

[If Female, is participant of childbearing potential?] Indicate if female subject is of childbearing potential. [Yes] will trigger the 'Pregnancy Test' CRF.

[Race (Mark all that apply):] select all race options that are applicable to the participant. If other is selected, enter in [Other Race, Specify] field.

The collection of race and ethnicity is based on the FDA Guidance for Industry on the Collection of Race and Ethnicity Data in Clinical Trials. Additional information on this guidance, can be obtained at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical

Medical and Surgical History

Enter all requested data fields. This CRF is set up as log form. Add 1 row for each medical condition and/or surgery.

The medical history will collect all active conditions and any relevant clinically significant condition which was diagnosed prior to date of Informed Consent/Assent. Record the participant's medical history (excluding Asthma medical history, which is collected in a separate eCRF) including medical conditions, diagnostic results, (drug) allergies and relevant physical examination findings (if applicable). Use standard medical terminology and only record one condition per line.

Any pre-existing condition present at the time the participant signs the ICF through the participant's last visit or 28 days (about 4 weeks) post last dose, whichever is longer, that worsen during the study, should be entered as an adverse event on the Adverse Events eCRF.

Any new medical conditions that occur after signing of the ICF but prior to IP administration should be recorded on the Medical and Surgical History eCRF and considered adverse events. AEs reported during this time that are serious should also be reported as an SAE per protocol Section 11.6.

Any adverse event a participant may experience post signing of ICF that meets the definition of Serious Adverse Events (SAE) per protocol Section 11.7.1 must be reported as an SAE on the SAE eCRF within 24 hours of the Investigator becoming aware of the SAE.

For history and treatment related to asthma, enter data on the 'Asthma History and Exacerbation History' eCRF.

If response to [Does the participant have any past medical conditions/ surgery, excluding Asthma history?] is No, then the rest of eCRF will be disabled for entry.

It is preferred that the complete date is provided as available; however, if the complete [Start Date] and/or [Stop Date] are not known for medical history, then at minimum, enter the Year. For unknown month enter UNK and unknown day enter UN.



Ongoing: Select [Ongoing], if the medical history condition is still present at the time the eCRF is being completed. If the medical condition resolves/ends during the course of the study, update the Medical History and enter the End Date.

The eCRF has pre-defined rows available for data entry. If more rows are needed, select [More Rows] at the bottom of the eCRF page as applicable. If you select 1, then one row will be added to the eCRF, if you select 5 or 10, then that many respective additional rows will be added.



Asthma History and Exacerbation History

Record participant's asthma history from the [First appearance of Asthma symptoms date]. For both [First appearance of Asthma symptoms date] and [Asthma Diagnosis Date], year must be known. For unknown month enter UNK and unknown day enter UN.

[Asthma maintenance treatment category at study entry] should be selected from the dropdown menu. If [Other, please specify] is selected, then [Specify Other Asthma maintenance treatment category at study entry] should be completed with the participant's current asthma maintenance treatment.

When [Asthma maintenance treatment category at study entry] is ICS or ICS + LABA or ICS + LABA + LAMA, then [What is the ICS dose level at screening (low, medium, or high dose) as per GINA 2024 Guidelines?] should be completed with appropriate entry from the dropdown list.

[Has the participant been on a stable dose of low-dose maintenance OCS, defined as ≤10 mg/day of prednisone or equivalent?] is a required field and should be entered before saving the page.

If [Has the participant received any biologic treatment for Asthma, including during a clinical trial?] is yes, add the relevant biologic treatmnet information to the Prior and Concomitant Medications form. In the field [If yes, add the relevant biologic treatment information to CM-Concomitant Medication Form] enter the CM number only (e.g. 1 or 2).

Record participant's Asthma exacerbation history in the previous 12 months.

[Number of Asthma exacerbations that resulted in hospitalization or ED visit within the previous 12 months prior to screening] Hospitalization includes observation for over 24 hours in an ED or urgent healthcare facility, to collect how many severe Asthma exacerbation in previous 12 months.

For the most recent historical Asthma exacerbation that resulted in systemic corticosteroids treatment and/or hospitalization a complete [Event start date] and [Event end date] are required.

If [Did the exacerbation require treatment with systemic glucocorticosteroids?] is Yes, enter this information on the Concomitant Medications eCRF.

V1a Follow-Up Phone Log

Participants who consent to participate through Screening Channel V1a will be contacted by telephone approximately every 4 weeks after Screening V1a to collect any changes in concomitant medications and any SAEs.

If [Not Done] is selected, the row will grey out.

Add “More rows” as needed to complete additional phone contacts with participants.

Vital Signs

Enter all requested data fields. The vital signs assessment per each visit is defined per protocol schedule of events. Ensure the vital signs are collected as per protocol, section 11.2.1. For instructions regarding Injection Day Vital Signs, see the section on Inject Day Vital Signs eCRF.

Any abnormal findings that are new or worsened in severity and clinically significant, in the opinion of the Investigator, will be recorded as an AE.

If response to [Were Vital Signs Collected?] is No, then the rest of eCRF will be disabled for entry. [If No, Reason:] should be completed.

If vital signs were conducted outside of an expected visit per schedule of events, enter the data on the Unscheduled Vital Signs eCRF.

If [Not Done] is selected for any parameter, the result field will grey out.

Please enter results in the unit specified on the eCRF.

Height/Weight

Height will only be measured at Screening Visit 1a or 1b. On all subsequent visits select No on [Was Height collected?] question and complete [If No, Reason] field with: Not required. The participants’ height must be measured without shoes.

Height will be recorded in centimeters (cm).

Enter unscheduled collections in the Unscheduled Visit section.

[Was Weight collected?] If Yes, record subject [Weight:] and [Collection Date:].
Note: Weight is defaulted to Kilogram (Kg)

[BMI]: this field is auto- calculated. Once weight and height are both entered click 'Update Value' to get the BMI. If weight or height changes value after the page has been saved, click 'Update Value' to re-calculate the BMI
Note: BMI will be calculated automatically to 1 decimal place.

Physical Exam

Complete and symptom-directed physical examinations will be performed at timepoints per the Protocol SOA (Table 5).

A complete physical examination will cover general appearance, dermatology, head, ears, eyes, nose, throat, respiratory, cardiovascular, abdominal, neurological, musculoskeletal, and lymphatic body systems.

Symptom-directed physical examinations can be performed at the Investigator's discretion at timepoints allowed per the SOA.

Findings from physical examinations will be documented in the appropriate sections of the eCRF. Abnormal findings identified during physical examination will be evaluated and documented by the Investigator as to whether the abnormality is an AE or medical history.

If [Was a Physical Exam performed?] is No, then complete [If No, reason].
Select [Not Required] when symptom-directed physical exam is not conducted per Investigator discretion.
If Yes, complete all fields on the form.

Select [Complete] or [Symptom-directed] for the appropriate visit.

The [Date of the Examination] is required and cannot be left Unknown.

For each [Body System] select the appropriate [Interpretation]. The [Finding] field will populate in the event that the Interpretation is indicated as Abnormal Clinically Significant. If Abnormal Clinically Significant, please enter adverse event or medical history number in the [Finding] field. [Body System Not Assessed] should be utilized for body systems not assessed.

Pregnancy Test

This form will be completed for all female participants recorded as 'Female' and if [If Female, is participant of childbearing potential?] is Yes on the Demographics CRF.

A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.
Record [Sample] as "Serum" or "Urine." Note that per the Schedule of Assessments, serum pregnancy test must be conducted at V1a and V1b. A urine pregnancy test must be conducted at V2 (unless V1b and V2 are on the same day, then a urine pregnancy test is not required), V8, and V9. Both serum and urine pregnancy tests will be analyzed at the local lab.

The Investigator must notify the Sponsor of any pregnancy by completing the Pregnancy Form and emailing it to the Sponsor **within 24 hours** after the Investigator becomes aware of the pregnancy. Email alerts will be disseminated to the Sponsor and safety representatives in the event of an on-study pregnancy.

Pregnancy is not considered to be an AE. Do not report as an SAE unless outcome of pregnancy meets SAE criteria (i.e., ectopic pregnancy, spontaneous abortion includes miscarriage and missed abortion, intrauterine fetal demise, neonatal death, congenital anomaly).

Enter unscheduled collections in the Unscheduled Visit section.

Laboratory Test

Central lab tests for Hematology, Chemistry and Urinalysis sample(s) are collected on this eCRF. Indicate in all sections whether the sample was collected per protocol requirements.

Local lab tests for Hematology, Chemistry and Urinalysis sample(s) are collected on a separate eCRF at V1b.

A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

Clinically significant abnormal laboratory values should also be entered as an AE. Record the specific diagnosis rather than the abnormal result, see Adverse Events section for additional information.

Concomitant Medications

All medications taken from 3 months prior to the participant's initial Screening Visit 1a or Visit 1b through the end of the trial, including those given in the urgent healthcare setting to treat the index acute asthma exacerbation are captured on this log form.

Any medication or vaccine (including over-the-counter or prescription medications, vitamins, and/or herbal supplements) received at Screening visits and throughout the trial must be recorded.

Any biologic drugs taken as treatment for asthma, including during a clinical trial, are to be entered in the Concomitant Medications form.

The [Start Date] and [End Date] allow for Unknown Day and Month. Year is required.

[Ongoing] is only selected in case there is no End Date. Ongoing status of all medications should be assessed at each visit and finally at the End of Trial visit for [End Date:] information.

If [Unit] or [Dose Form] or [Route] or [Frequency] or [Prophylaxis, Specify] is "Other" complete the [Other, Specify] field accordingly.

If [Frequency] is pro re nata (PRN) and the medication is related to asthma treatment, please enter approximate actual frequency instead of selecting PRN. When the frequency changes, add a new entry to capture the intensification or reduction in pharmacological treatment.

> Note: the exception to the above is PRN rescue medication changes in frequency. This information will be reported by the participant in the daily e-Diary. PRN rescue medication use should only be captured once in the Concomitant Medications eCRF.

Depending on the selection for [Indication], populate the remaining fields. Select all that apply

- Medical History: Refer to the Medical History (MH) eCRF for the corresponding MH and enter the MH number. If medication is related to MH and is ongoing at the time of ICF. Leave End Date blank and check "ongoing." The medication will not need to be entered again for the duration of the study.
- Asthma: Select asthma if medication is for treatment of asthma.
- Asthma Exacerbation: Check either Index or Subsequent for the question 'Is exacerbation an index or subsequent exacerbation?' If medication is for a subsequent asthma exacerbation, please provide the associated Subsequent Exacerbation number.
- Adverse Event: Select if medication is for treatment of an adverse event. Refer to the Adverse Event (AE) eCRF for the corresponding AE number.
- Procedures: Select Procedures if medication is used for a procedure or following a procedure. Refer to the Concomitant Procedures eCRF for the corresponding Procedure number.
- Prophylaxis: Select if medication is used for prophylaxis of any condition. Please provide details on the type of prophylaxis taken by the participant.
- "Other" is *only* to be used if the reason for administration is *not* an Adverse Event, Medical History, asthma, asthma exacerbation, or Prophylaxis e.g., because the medication has no

specific therapeutic indication (e.g., nutritional supplements). Please use this option and make your description as specific as possible.

Select [More rows] to add rows to this log form.

The Medical Monitor should be contacted if there are any questions regarding prior or concomitant medication or procedures.

Concomitant Procedures

[Non-Drug Therapies/Procedures]: Provide the procedure or non-medication the treatment name. Enter one term per line. Examples of non-drug therapies/procedures include but are not limited to invasive/non-invasive ventilation (Continuous Positive Airway Pressure [CPAP], Bilevel Positive Airway Pressure [BiPAP]), endotracheal intubation, bronchial thermoplasty, and arterial blood gas (ABG) analysis.

If ventilation was administered during asthma exacerbation episodes (Index or Subsequent), please record it in the Concomitant Procedure eCRF.

If [Did the participant have any non-drug therapies or procedures during the study?] is Yes, the form will generate fields to complete.

The [Start Date] and [End Date] allow for Unknown Day and Month. Year is required.

[Ongoing] is only selected in case there is no End Date. Ongoing status of all therapies should be assessed at each visit and finally at the End of Trial visit for [End Date:] information.

If [Frequency] is “Other, Specify,” complete [Specify Other Frequency].

Depending on the selection for [Indication], populate the remaining fields. Select all that apply.

- Medical History: Refer to the Medical History (MH) eCRF for the corresponding MH and enter the MH number. If medication is related to MH and is ongoing at the time of ICF leave End Date blank and check “ongoing.” The medication will not need to be entered again for the duration of the study.
- Asthma: Select asthma if medication is for treatment of asthma.
- Asthma Exacerbation: Check either Index or Subsequent for the question ‘Is exacerbation an index or subsequent exacerbation?’ If medication is for a subsequent asthma exacerbation, please provide the associated Subsequent Exacerbation number.
- Adverse Event: Select if medication is for treatment of an adverse event. Refer to the Adverse Event (AE) eCRF for the corresponding AE number.

- Procedures: Select Procedures if medication is used for a procedure or following a procedure. Refer to the Concomitant Procedures eCRF for the corresponding Procedure number.
- Prophylaxis: Select if medication is used for prophylaxis of any condition. Please provide details on the type of prophylaxis taken by the participant.
- "Other" is *only* to be used if the reason for administration is *not* an Adverse Event, Medical History, asthma, asthma exacerbation, or Prophylaxis e.g., because the medication has no specific therapeutic indication (e.g., nutritional supplements). Please use this option and make your description as specific as possible.

Select [More rows] to add rows to this log form.

The Medical Monitor should be contacted if there are any questions regarding prior or concomitant medication or procedures.

Any Adverse Events?

All AEs regardless of causality will be recorded. If [Has the participant experienced any Adverse Events?] is Yes and the eCRF is saved, the Adverse Events eCRF will populate to collect further information.

Adverse Events

This form is completed if the participant has experienced any Adverse Events. To add a new "Adverse Events" form, select "Adverse Events (add new form) from the Form View within the Log Forms folder.

[AE #]: This field should be unique and sequentially assigned. This is a manual field. Please check prior AE # added to assist with consistent numbering. This field will be utilized to reference AE as an Indication across other CRFs like Concomitant Medications/Procedures, Exacerbation History, etc.

[AETERM]: List only one adverse event per log line. This field will be coded using the information provided verbatim.

- Record the specific diagnosis rather than abnormal results, e.g., "ALT 120 U/L" is not allowed.
- Record only one term per row, e.g., the subject happened "Nausea and Vomiting," should be provided as "Nausea" and "Vomiting" separately.
- Do not use abbreviations, e.g., GERD should be spelled out as Gastroesophageal reflux disease.
- Please do not enter the Medications or Non-drug Treatments.

- If a pre-existing medical condition from the Medical History CRF worsens or increases in severity, record this change in condition as an Adverse Event. Use the same event term that was recorded in the Medical History CRF and modify it to note worsening.
- Avoid recording duplicated AEs if an ongoing AE or MH has already been entered.
- If applicable, organ or body part/system involved should be specified to allow for accurate coding. For example: “Neck Pain” and “Abdominal Pain.”
- Do not record “pregnancy” as an Adverse Event.

[Start Date] and [End Date] must be a complete date. Partial dates are not acceptable. If an AE is serious, indicate the dates the AE becomes/is considered serious on the SAE CRF separately. Partial dates are not acceptable.

[Ongoing] is only selected in case there is no End Date. Ongoing status of all AEs should be assessed at each visit and finally at the End of Trial visit for [End Date:] information. In the event a participant passes away on study, the date of death should be entered as the [End Date:] for all ongoing AEs.

Select the appropriate [AE Category (Select all that apply)], this is a required field. “Not Applicable” should be selected in the event none of the categories apply.

[DILI] **Suspected Drug-induced Liver Injury (DILI)**
DILI refers to a liver injury induced by various chemical drugs, biological products, herbal medicines and their metabolites or even excipients. Hy's Law can facilitate assessment of severe liver injury predominated by hepatocellular injury. It specifically refers to cases that meet all of the following 3 criteria:
For participants with normal liver function tests at baseline:

1. ALT or AST ≥ 3× ULN during Treatment Assessment Period, and
2. Total bilirubin > 2× ULN during Treatment Assessment Period; without cholestasis at baseline (serum alkaline phosphatase [ALP] increased), and
3. No other identifiable causes explaining the simultaneous elevation of aminotransferases and total bilirubin, such as viral hepatitis A, B, C or E or other acute liver diseases, or concomitant use of other drugs that may induce liver injury.

[AESI] **Adverse Event of Special Interest (AESI)**
An AESI may be serious or non-serious and is one of scientific and medical concern specific to the Sponsor's product mechanism of action, for which ongoing monitoring may be appropriate. Such an event might warrant further investigation to characterize and understand it and rapid communication by the trial Sponsor to other regulatory authorities may also be warranted.
For this trial, AESIs shall include:

- Conjunctivitis
- Keratitis

- Severe injection site reactions persisting for more than 24 hours: defined as injection site reactions persisting for more than 24 hours and the severity is CTCAE Grade ≥3.
- Parasitic and opportunistic infections: whether the infection is classified as opportunistic infection will be determined after discussion with medical monitor. When reporting opportunistic infection, the Investigators will refer to protocol Appendix J Table 7.
- Anaphylaxis: defined according to the symptoms shown in protocol Appendix J Table 8.

[UADE] **Unanticipated Adverse Device Effect (UADE)**
According to 21 CFR 812.3(s), a UADE means any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, a device (pre-filled syringe in this case), if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan or application (including a supplementary plan or application), or any other unanticipated serious problem associated with a device that relates to the rights, safety, or welfare of participants.

[Severity] is important to distinguish between serious and severe AEs. The Investigator will use the CTCAE Version 5.0 to assist in the determination of severity and clinical significance. The following represents CTCAE grading of AE severity:

- Grade 1: asymptomatic or mild symptoms or clinical or diagnostic observations only or intervention not indicated.
- Grade 2: minimal, local, or noninvasive intervention indicated or limiting age-appropriate instrumental activities of daily living (ADL). Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.
- Grade 3: hospitalization or prolongation of hospitalization indicated or disabling or limiting self-care ADLs. Self-care ADLs refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications and not bedridden.
- Grade 4: Life-threatening consequences with urgent intervention indicated.
- Grade 5: Death related to AE.

[Serious] An AE or suspected adverse reaction is considered “serious” if, in the view of either the Investigator or Sponsor, it results in any of the following outcomes:

- Death
- A life-threatening AE (i.e., presented an immediate risk of death from the event as it occurred. This criterion is not intended to include an AE that, had it occurred in a more severe form, might have caused death.)
- Inpatient hospitalization or prolongation of existing hospitalization
- A persistent or significant incapacity to conduct normal life functions
- A congenital anomaly/birth defect
- Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the participant and may require medical or surgical

intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

The following events do not meet the definition of an SAE: hospitalization for elective treatment of a pre-existing condition that does not worsen from baseline, hospitalizations for a standard procedure for IP administration, routine monitoring of the studied indication not associated with any deterioration in condition, social or convenience admission to a hospital, prolongation of a hospitalization for social or convenience reasons not associated with the occurrence of an AE, or hospitalization or an emergency room visit that lasts less than 24 hours that does not meet the criteria of an important medical or a life-threatening event.

If [Serious:] is selected as Yes, the Serious Adverse Event eCRF will populate for entry in the Log Forms Subject Information folder to collect additional details.
Email alerts will be disseminated to the Sponsor and safety representatives when [Serious:] is selected as Yes.

[Serious Adverse Event #:] This field should be unique and sequentially assigned. This is a manual field. Please check prior SAE # added to assist with consistent numbering. This SAE # should match the number entered in the SAE CRF.

[Causality] relates to the IP administration according to the following guidelines:

- Possibly Related: the AE is known to occur with the IP, there is a reasonable possibility that the IP caused the AE, or there is a temporal relationship between IP and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the IP and the AE.
- Unlikely Related: there is not a reasonable possibility that the administration of the IP caused the event, there is no temporal relationship between the IP and event onset, or an alternate etiology has been established.

[Action Taken with Study Drug:] Select ‘Dose not changed’ if full dose of study drug was already administered. Select ‘Dose Interrupted’ if AE resulted in interruption of full dose during administration. Select ‘Not Applicable’ if AE occurs prior to dosing.

[Outcome] Select outcome of the AE from the drop-down list: Resolved, Resolved with Sequalae, Not Resolved, Unknown, and Death. In the event a participant passes away on study, only the AE that is the primary reason for death should have an outcome of ‘Death’ and other AE in this case should be ‘Not Resolved’.

Serious Adverse Events

This form will be completed if [Serious] is Yes on the "Adverse Events" eCRF. Complete the SAE eCRF within 24 hours of awareness.

Only enter one SAE per eCRF, add a new instance of the SAE eCRF for additional SAEs.

Enter the [AE#] that correspond to the event term reported from the "Adverse Events" eCRF.

[SAE #]: This field should be unique and sequentially assigned. This is a manual field. Please check prior SAE # added to assist with consistent numbering.

Mark all that apply when selecting the [Serious Criteria Met].

If the participant is hospitalized, complete the [Date of Inpatient Hospitalization] and [Date of Inpatient Hospitalization Discharge], partial dates are not acceptable.

> Note: If the SAE criteria is prolongation of existing hospitalization, then [Date of Inpatient Hospitalization] refers to the day when the inpatient must prolong the hospitalization due to SAE.

If the participant has a fatal outcome, complete if the redacted autopsy report has been uploaded or emailed to: connectsafety.sm@thermofisher.com and PV@connectpharm.com.
[Date of First Dose of Study Drug:] is a derived field, populating from the Study Drug Administration eCRF.

Any updates saved to the SAE (or it's supporting parent AE) eCRF will result in an email alert to the Safety and Sponsor representatives.

To add a new "Serious Adverse Events" form, select the "Serious Adverse Events (add new form) from the Forms View.

12-Lead ECG (Local Lab)

Measurements will be performed with the participant resting in a supine position for approximately 5 minutes before each reading and should be carried out after measurement of vital signs and before spirometry. ECGs should be performed before blood is drawn during visits requiring blood draws.

If [Was a 12-Lead ECG performed?] is Yes, complete all fields on the form. [Date Performed] may not be Unknown.

Record the protocol defined assessments in the specified units.

The [QTcF] field is auto-calculated. Once [RR interval] and [QT interval] are both entered, click 'Update Value' to get the QTcF. If either of these variables change, click 'Update Value' again to re-calculate the QTcF.

If [Interpretation] is indicated as Abnormal, enter the associated Adverse Event number or Medical History Number in the [If Abnormal, Specify:] field.

Enter unscheduled collections in the Unscheduled Visit section.

PK Sample

If [Were PK sample(s) collected] is Yes, complete the [Collection Date] and [Collection Time].

A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

Biomarker Sample

If [Were biomarker sample(s) collected?] is Yes, complete the [Collection Date] and [Collection Time].

A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

Immunogenicity Sample (ADA and NAb)

If [Were Immunogenicity (ADA and NAb) sample(s) collected?] is Yes, complete the [Collection Date] and [Collection Time].

A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

Chest X-ray or CT

A chest X-ray (or CT scan), for purposes of determining participant eligibility, will be performed only at Screening Visit 1b if no chest imaging (X-ray or CT) is available within the previous year or if clinically indicated.

[Was the chest X-ray/CT performed at this visit?] Enter yes if performed. Enter no if a historical (within 12 months) chest imaging is available or if not done.

If utilizing a historic (within 12 months) chest X-ray or CT scan, enter "Historical (within 12 months) chest X-ray/CT available" in the field [If No, Reason:].

Enter [Date Performed] for the date the chest X-ray or CT scan was actually performed. This date may be the same as the visit date, or within the past 12 months.
Additional information is requested when [Interpretation:] is Abnormal.

Enter unscheduled collections in the Unscheduled Visit section.

Hematology (Local Lab)

Local Labs will be collected during Screening Visit 1b to expedite eligibility. At other visits, labs will be collected centrally on the "Laboratory Test" eCRF.

Enter the results in the corresponding units available. Note that you will need to manually enter the lab normal ranges.

Clinically Significant is only entered when the result is not within the laboratory normal ranges. Otherwise, it should be blank.

Enter unscheduled collections in the Unscheduled Visit section.

Chemistry (Local Lab)

Local Labs will be collected during Screening Visit 1b to expedite eligibility. At other visits, labs will be collected centrally on the "Laboratory Test" eCRF.

Enter the results in the corresponding units available. Note that you will need to manually enter the lab normal ranges.

Clinically Significant is only entered when the result is not within the laboratory normal ranges. Otherwise, it should be blank.

Enter unscheduled collections in the Unscheduled Visit section.

Urinalysis (Local Lab)

Local Labs will be collected during Screening Visit 1b to expedite eligibility. At other visits, labs will be collected centrally on the "Laboratory Test" eCRF.

Enter the results in the corresponding units available. Note that you will need to manually enter the lab normal ranges.

Clinically Significant is only entered when the result is not within the laboratory normal ranges. Otherwise, it should be blank.

Enter unscheduled collections in the Unscheduled Visit section.

Smoking History

If [Was the Smoking History collected?] is Yes, complete the [Assessment Date].

[What is the participant's Smoking History?] Former smokers are defined as individuals who have stopped smoking for at least 6 months prior to Screening (Visit 1b). This field is IRT integrated at V1b and will be read only.

[Approximate Smoking Start Date] and [Approximate Smoking Cessation Date] will allow an Unknown entry for Day and Month. The Year is required. Use the format UN-UNK-YYYY for unknown day and month. Use the format UN-MMM-YYYY for unknown day. If the participant is a non-smoker, leave these fields blank.

[Estimated Number of Pack-Years] should be calculated as defined in Protocol Section 11.1.2. Number of pack years = ((number of cigarettes per day / 20) × number of years smoked) (e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years both equal 10 pack-years). If participant is a non-smoker, enter 0 pack-years.

One pack of cigarettes a day for 1 year is equivalent to:

- 1 cigar or pipe per day for 1 year
- Smoked hookah or shisha =1 session per day for 1 year
- Vaped e-cigarettes =0.5 mL e-liquid per day for 1 year, or =1 cartridge/tank/pod per day for 1 year
- 1 use of marijuana per day for 1 year

[Smoking Method (Select all that apply)]: If participant is a non-smoker, leave this field blank. Otherwise, select all that apply.

Smoking Status Changes

Changes in smoking status are captured for consented participants through EOT visit. Pharmacological smoking cessation therapies will be recorded on Concomitant Medication eCRF.

[Smoking Start Date] and [Smoking Cessation Date] allow for Unknown day. Month and Year are required. Use the format UN-MMM-YYYY for unknown day.

Enter unscheduled collections in the Unscheduled Visit section.

Index Asthma Exacerbation

This eCRF indicates the baseline exacerbation of the participant at the V2 visit.

Complete dates are required throughout the eCRF.
Times are to be reported in 24-hour format.

[Did the exacerbation result in a hospitalization at V2?] Based on the response to this question, the participants' schedule will trigger visits V3 and V4, or it will skip these visits and populate next the V5 visit. If [Did the exacerbation result in a hospitalization at V2?] is Yes or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is Yes, then visits V3 and V4 will appear in the participant's schedule. If [Did the exacerbation result in a hospitalization at V2?] is No or if [Does the participant consent to having optional spirometry measurements taken on Day 2 and Day 3?] is No, then V3 and V4 will be skipped and the V5 visit will appear in the participant's schedule.

If ventilation was administered, please record it in the Concomitant Procedure eCRF.

In the event the Index Asthma Exacerbation requires hospitalizations/interventions which are ongoing beyond the V2 visit, the exacerbation information should be followed to completion and entered on the 'Index Asthma Exacerbation Follow-Up' eCRF.

Index Asthma Exacerbation Follow-Up

This eCRF is utilized to follow any hospitalizations/interventions which were ongoing from the V2 'Index asthma Exacerbation' eCRF.

This eCRF automatically appears for participants for which [Did the exacerbation result in a hospitalization at V2?] is Yes on the Index Asthma Exacerbation CRF. This eCRF will not be available for participants who were not hospitalized at V2 because the index exacerbation is considered resolved.

Complete dates are required throughout the eCRF.
Times are to be reported in 24 hr. format.

If ventilation was administered, please record it in the Concomitant Procedure eCRF.

An Unscheduled Visit should be utilized to complete this form if:

- Participant becomes hospitalized or re-hospitalized for the index exacerbation after V2 and within 7 days of onset or
- Participant visits or re-visits the ED for the index exacerbation after V2 and within 7 days of onset

After 7 days the Subsequent Asthma Exacerbation CRF should be utilized as the event is considered a new exacerbation. The protocol states that exacerbations separated by less than 7 days will be treated as a continuation of the same exacerbation. Courses of corticosteroids separated by 7 days or more should be treated as separate acute exacerbations.

Subsequent Asthma Exacerbation Episode

Enter 1 eCRF for each subsequent Asthma Exacerbation Episode after the Index Asthma Exacerbation resolves.

An exacerbation should be considered subsequent if it occurs on or after Day 7, unless the Index asthma exacerbation is still ongoing. The subsequent exacerbation CRF appears starting on Visit 6 (Day 7).

[Episode #] This field should be unique and sequentially assigned. This is a manual field. Please check prior subsequent asthma exacerbation episode # added to assist with consistent numbering.

Note: The index asthma exacerbation should not be counted. Please count starting from the first subsequent asthma exacerbation.

Complete dates are required throughout the eCRF.
Times are to be reported in 24 hr. format.

If ventilation was administered, please record it in the Concomitant Procedure eCRF.

Complete the SAE CRF if the exacerbation meets SAE criteria.

Enter unscheduled collections in the Unscheduled Visit section.

Health Care Resource Utilization

Complete dates are required throughout the eCRF.
Times are to be reported in 24-hour format.

Enter unscheduled collections in the Unscheduled Visit section.

Injection Day Vital Signs

Utilize this eCRF to record Vital signs requirements at the V2 visit.
Enter all requested data fields. Injection day vital signs are to be collected at timepoints specified in protocol section 11.2.1. Fields are available in the eCRF for any other timepoints that may be collected.

Any abnormal findings that are new or worsened in severity and clinically significant, in the opinion of the Investigator, will be recorded as an AE.

If response to [Were Vital Signs Collected?] is No, then the rest of eCRF will be disabled for entry. [If No, Reason:] should be completed.

If [Not Done] is selected for any parameter, the result field will grey out. Please enter results in the unit specified on the eCRF.

Study Drug Administration

Utilize this eCRF to record information relating to IP Administration at the V2 visit.

The following fields on this eCRF are IRT integrated and are read only. In the event that a kit is not replaced, the replacement fields will appear blank.

[Kit Number 1:]
[Kit Number 2:]
[Replacement Kit Number 1A:]
[Replacement Kit Number 2A:]
[Replacement Kit Number 1B:]
[Replacement Kit Number 2B:]

A complete [Date Administered:] is required.
Record [Start Time of Injection:] and [End Time of Injection:] in a 24-hour format.

[Start Time of Injection:] should indicate the time the first injection began.
[End Time of Injection:] should indicate the time the last injection was completed.

In the event that a participant does not receive all four injections, indicate ‘Not Done’ in the corresponding [Anatomical Location:] field which correlates with doses not received.

Injection Site Reaction Assessment

For assessments conducted at V2, record injection site reaction assessment at 30 minutes post-injection and 2 hours post-injection using the drop down options available for [Timepoint].

For assessments conducted after V2, select 'Not applicable' for the [Timepoint] field. Only one timepoint needs to be completed. The other row may be left blank.

A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

Report clinically significant findings on the Adverse Event eCRF.

Enter unscheduled collections in the Unscheduled Visit section.

ACQ-5 Assessment

A complete [Completion Date:] is required.

Modified Borg Dyspnea Scale Assessment

A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

Spirometry/FeNO/Peak Flow

This eCRF is only available in the V1b visit schedule.

If [Was the Spirometry assessment completed?] is No, complete [If No, Reason].

If [Was the Peak Exploratory Flow assessment completed?] is required.

If [Was the Peak Exploratory Flow assessment completed?] is Yes, complete the [Timepoint], [Collection Date:] and [Collection Time:].
A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

If [Was the FeNo assessment completed] is No, complete [If No, Reason].
If Yes, complete the [Collection Date] and [Collection Time].

> Note: in the event a FeNo assessment is Not Required at the time of Spirometry Assessment, select 'Not Required' for this section. See Protocol Schedule of Assessments.

Spirometry/FeNO

If [Was the Spirometry assessment completed?] is No, complete [If No, Reason].

If Yes, complete the [Timepoint], [Collection Date:] and [Collection Time:].
A complete [Collection Date:] is required.
Record [Collection Time:] in a 24-hour format.

If [Was the FeNO assessment completed] is No, complete [If No, Reason]. If Yes, complete the [Collection Date and Time].

> Note: in the event a FeNO assessment is Not Required at the time of Spirometry Assessment, select 'Not Required' for this section. See Protocol Schedule of Assessments.

Enter unscheduled collections in the Unscheduled Visit section.

End of Trial

This eCRF is required for all participants who received IP administration on V2.

A complete date is required for [Date of Trial Completion/Termination:]. In the event a patient passes away after V2 visit, populate the date of death in this field.

If [Reason for Trial Completion/Termination:] is Adverse Event, ensure this information is entered on the corresponding AE eCRF.

If [Reason for Trial Completion/Termination:] is Death, ensure all ongoing log form entries are updated with an [End Date:] consistent with the date of death.

If [Death Details:] is checked as 'Not Due to Asthma,' add details on cause of death in [Specify Cause of Death:]

Investigator Signatures

Principal Investigators are required to review and apply an electronic signature for each participant's CRF. Applying this signature is the Investigator's attestation that the data entered in the database is complete and accurate. The CRA informs the Investigator when the CRFs are ready for review and signature. This notification occurs after the CRFs have been cleaned, verified against the source documents, and frozen. Investigators may be informed to sign eCRFs prior to freezing the database. Re-signing may be required if eCRFs have been updated due to new information or query response.

The Investigator Signature may be applied to an individual form, or the Investigator may batch sign the entire casebook.

To Sign an individual form, navigate to that form, and review the data entered. At the bottom of the form, click on the Sign button to apply your credentials. A popup window will appear. Add your username and password. You will see that your signature has been applied.

To Batch sign a participant's casebook after the Investigator has reviewed the data entered, click the Sign Subject actions button on the participant's home page. This is located at the top of the home page. A popup window will appear. Add your username and password. You will see that your signature has been applied to the participant's entire casebook.

Certificate Of Completion

Envelope Id: 81159AB3-A6E6-406C-BCBA-65EF5CD9A3A3 Status: Completed
Subject: Complete with Docusign: CBP-201-206_eCRF Completion Guidelines_eCCGs_v1.0_02JUN2025.pdf
GRC:
Vendor Name:
Source Envelope:
Document Pages: 54 Signatures: 2 Envelope Originator:
Certificate Pages: 5 Initials: 0 Celissa Williams
AutoNav: Enabled 6005 Hidden Valley Rd Ste 170
EnvelopeId Stamping: Disabled Carlsbad, 92011-4224
Time Zone: (UTC-08:00) Pacific Time (US & Canada) Celissa.Williams@precisionformedicine.com
IP Address: 165.225.8.198

Record Tracking

Status: Original Holder: Celissa Williams Location: DocuSign
6/2/2025 2:09:05 PM Celissa.Williams@precisionformedicine.com

Signer Events	Signature	Timestamp
Bryn Natale bnatale@connectpharm.com Clinical Trials Assistant Manager Connect Biopharma Security Level: Email, Account Authentication (Required)	Signed by: Signer Name: Bryn Natale Signing Reason: I approve this document Signing Time: 02-Jun-2025 | 2:32:04 PM PDT B9E47875BC2441C38B78B2B0F66E5618 Signature Adoption: Drawn on Device Signature ID: B9E47875-BC24-41C3-8B78-B2B0F66E5618 Using IP Address: 157.131.110.216 With Signing Authentication via Docusign password With Signing Reasons (on each tab): I approve this document	Sent: 6/2/2025 2:21:02 PM Viewed: 6/2/2025 2:27:42 PM Signed: 6/2/2025 2:32:21 PM
Electronic Record and Signature Disclosure: Accepted: 6/2/2025 2:27:42 PM ID: 1ed98203-ba08-4880-a01d-0712c6eda47d		
Celissa Williams celissa.williams@precisionformedicine.com Principal Clinical Data Manager Precision For Medicine - Part 11 Security Level: Email, Account Authentication (Required)	Celissa Williams Signature Adoption: Pre-selected Style Signature ID: 474BE319-B697-474A-96CD-69EFE54052A7 Using IP Address: 165.225.8.198 With Signing Authentication via Docusign password With Signing Reasons (on each tab): I am the author of this document	Sent: 6/2/2025 2:21:01 PM Viewed: 6/2/2025 4:14:36 PM Signed: 6/2/2025 4:16:11 PM
Electronic Record and Signature Disclosure: Accepted: 6/2/2025 4:14:36 PM ID: 48d2ec10-52ff-4f03-a8e0-ef8f7717352e		

In Person Signer Events	Signature	Timestamp

Editor Delivery Events	Status	Timestamp

Agent Delivery Events	Status	Timestamp

Intermediary Delivery Events	Status	Timestamp

Certified Delivery Events	Status	Timestamp

Carbon Copy Events	Status	Timestamp

Witness Events	Signature	Timestamp

Notary Events	Signature	Timestamp

Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	6/2/2025 2:21:02 PM
Certified Delivered	Security Checked	6/2/2025 4:14:36 PM
Signing Complete	Security Checked	6/2/2025 4:16:11 PM
Completed	Security Checked	6/2/2025 4:16:11 PM

Payment Events	Status	Timestamps

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Precision for Medicine (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a $0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Precision for Medicine:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To advise Precision for Medicine of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Precision for Medicine

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Precision for Medicine

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;

ii. send us an email to RARE.DocuSign@precisionformedicine.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: https://support.docusign.com/guides/signer-guide-signing-system-requirements.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Precision for Medicine as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Precision for Medicine during the course of your relationship with Precision for Medicine.